Mesoridazine metabolite

The presence of metabolites with varying pharmacological profiles (e.g., some may be more effective than their parent compound [e.g., mesoridazine] some may not reach the brain [e.g., sulfoxides], and some may have greater toxicity than the parent compound)... 

CINACALCET BUPROPION T plasma concentrations of these substrates, with risk of toxic effects Bupropion and its metabolite hydroxybupropion inhibit CYP2D6 Initiate therapy of these drugs, particularly those with a narrow therapeutic index, at the lowest effective dose. Interaction is likely to be important with substrates for which CYP2D6 is considered the only metabolic pathway (e.g. hydrocodone, oxycodone, desipramine, paroxetine, chlorpheniramine, mesoridazine, alprenolol, amphetamines, atomoxetine)... 

Mesoridazine is a major metabolite of thioridazine. Therapeutic Concentration. 

Disposition in the Body. Sulforidazine is an active metabolite of mesoridazine and thioridazine. 

Disposition in the Body. Readily absorbed after oral administration. It is metabolised mainly by sulphoxidation to give the side-chain sulphoxide (mesoridazine), the side-chain sulphone (sulforidazine), both of which are active, and the ring sulphoxide and sulphone A-demethylation also occurs. Other metabolites are produced by combinations of these metabolic reactions. It is metabolised in the liver, secreted in the bile, and excreted mainly in the faeces. Less than about 10% of a dose is excreted in the... 

The concentration of the active metabolite mesoridazine falls more markedly. Phenytoin and phenobarbital reduce furosemide absorption. 

The alkylpiperidine group (Nos. 4-6) tends to be less effective and exhibits little antiemetic influence. However, they appear to have less extrapyramidal effect and may be considered to have the least toxicity of the four groups. Thioridazine has been reported to have the possibly unique property of inhibiting premature or nocturnal ejaculation in males without impairment of potency or orgasm. The active metabolite mesoridazine has not been similarly evaluated. 

Thioridazine (No. 5) undergoes an additional sulfoxidation at the 2-thiomethyl group. However, in this case the metabolite produced is active and marketed as mesoridazine (No. 4). 

Mesoridazine, a metabolite of thioridazine, is thought to exert its antipsychotic effects by postsynaptic blockade of CNS dopamine receptors, thereby inhibiting dopamine-mediated effects. Mesoridazine has many other central and peripheral affects it produces both alpha and ganglionic blockade and counteracts histamine- and serotonin-mediated activities. Mesoridazine and thioridazine cause fewer movement disorders (see Phenotheazine Derivatives). Mesoridazine is metabolized to inactive metabolites, which are excreted by the kidneys. Overdosage of mesoridazine causes CNS depression characterized by deep, unarousable sleep, convulsive seizures, and cardiac arrhythmias (see also Table 2). 

Thioridazine undergoes extensive side-chain degradation to active metabolites, such as mesoridazine, and inactive metabolites. 

Haloperidol (Haldol), risperidone (Risperdal), loxapine (Loxitane), ziprasidone (Geodon), quetiapine (Seroquel), clozapine (Clozaril), aripiprazole (Abilify), and thioridazine (Mellaril) are targeted in this solid phase extraction (SPE), liquid chromatography— tandem mass spectrometry (LC-MS/MS) method. Both 9-hydroxy-risperidone (Paliperiodone), an equipotent metabolite, and mesoridazine (Serentil) are also included in this method as they are pharmacologically active major metabolites of risperidone and thioridazine, respectively (4). Olanzapine (Zyprexa) can be quantified with this instrument method however, the extraction method is a liquid-liquid basic extraction (see Note 1). Due to the subsequent administration of antidepressants in conjunction with antipsychot-ics, this method can also be used for many of the common antidepressants, including the selective serotonin reuptake inhibitors (SSRIs) (see Note 2). 

---